Treatment of IgA nephropathy

Česká verzia

Authors: K. Matoušovic ^1,2; J. Mestecky ^3,4,5; M. Tomana ^3,4; J. Novák ³
Authors place of work: Interní klinika 2. lékařské fakulty UK a FN Motol, Praha, přednosta prof. MUDr. Milan Kvapil, CSc. ¹; I. interní klinika Lékařské fakulty UK a FN Plzeň, přednosta doc. MUDr. Milan Matějovič, Ph. D. ²; Department of Microbiology University of Alabama at Birmingham, Birmingham, USA, přednosta prof. David D. Chaplin ³; Department of Medicine University of Alabama at Birmingham, Birmingham, USA, přednosta prof. Edward Abraham ⁴; Ústav mikrobiologie a imunologie 1. lékařské fakulty UK a VFN Praha, přednosta doc. MUDr. Ivan Šterzl, CSc. ⁵
Published in the journal: Vnitř Lék 2008; 54(3): 239-244
Category: Review

Summary

IgA nephropathy is the most common cause of chronic renal failure among primary glomerulonephritides. During the last decade, there was a remarkable progress in understanding its pathogenesis. A number of therapeutic trials has been published that shed light on its treatment. ACEI and AT₁R antagonists (sartans) or their combination represent the cornerstone of therapy of IgA nephropathy. However, this treatment is not given to patients having optimal blood pressure, normal glomerular filtration rate, proteinuria less than 0.3 g/24 h, mild abnormalities in renal biopsy, and stationary course of the disease. The medication is administered in a maximal tolerated dose to patients with active, progressing disease. ACEI and AT₁R antagonists are also drugs of the first choice in patients with proteinuric IgA nephropathy. However, if proteinuria does not decrease significantly within 3 months from the beginning of this treatment, administration of glucocorticosteroids is recommended. On the basis of prospective, controlled clinical trials and metaanalyses of other therapeutic studies, it has been concluded that glucocorticosteroids decrease proteinuria and slow down the decline of renal function. A complete remission of proteinuria is the aim of the treatment. The effectiveness of cyclophosphamide in active forms of IgA nephropathy, described in some studies, was not confirmed by metaanalyses. Nevertheless, cyclophosphamide may be effective in some patients with rapidly deteriorating renal function and active morphological findings with cellular extracapillary proliferation.

Key words:
IgA nephropathy - ACE inhibitors - AT₁R antagonists - glucocorticosteroids

Zdroje

1. Assadi FK. Value of urinary excretion of microalbumin in predicting glomerular lesions in children with isolated microscopic hematuria. Pediatr Nephrol 2005; 20: 1131-1135.

2. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-148.

3. Bartosik LP, Lajoie G, Sugar L et al. Predicting progression in IgA nephropathy. Am J Kid Dis 2001; 38: 728-735.

4. Berl T. Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: the case for AT1 receptor antagonist. J Am Soc Nephrol 2004; 15(Suppl 1): S71-S76.

5. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24: 11-25.

6. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe IgA nephropathy: a comparison to patients receiving treatment with other antihypertensive drugs and to patients receiving no therapy. Am J Kidney Dis 1994; 23: 247-254.

7. Cattran DC. Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy? J Am Soc Nephrol 2007; 18: 1633-1634.

8. Coppo R, Peruzzi L, Amore A et al. IgACE: A placebo-controlled randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18: 1880-1888.

9. Dillon JJ. Fish oil for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997; 8: 1739-1744.

10. Donadio JV Jr, Bergstralh EJ, Offord KP et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994; 331: 1194-1199.

11. Frisch G, Lin J, Rosenstock J et al. Mycophenolate mofetil (MMF) versus placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized control trial. Nephrol Dial Transplant 2005; 20: 2139-2145.

12. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29: 829-842.

13. Hogg RJ, Leem J, Nardelli N et al. Clinical trial to evaluate ω-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1: 467-474.

14. Hotta O, Miyazaki M, Furuta T et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kid Dis 2001; 38: 736-743.

15. Chábová V, Tesař V, Žabka J et al. Dlouhodobé podávání cyklosporinu A pacientům s IgA nefropatií. Čas Lék Čes 1996; 135: 803-806.

16. Lai KN, Lai FM, Li PKT. Cyclosporine treatment of IgA nephropathy: A short-term control trial. BMJ (Clin Res Ed) 1987; 295: 1165-1168.

17. Laville M, Alamartine E. Treatment options for IgA nephropathy in adults: a proposal for evidence based strategy. Nephrol Dial Transpl 2004; 19: 1947-1951.

18. Luno J, Praga M, de Vinuesa SG. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des 2005; 11: 1291-1300.

19. Maes BD, Oyen R, Claes K et al. Mycophenolate mofetil in IgA nephropathy: results of a 3 year prospective placebo controlled trial. Kidney Int 2004; 65: 1842-1849.

20. Matoušovic K, Martínek V. IgA nefropatie. Užití moderních laboratorních technik a biopsie ledviny v diagnostice. Vnitř Lék 2003; 47: 869-873.

21. Matoušovic K, Mestecky J, Tomana M et al. Imunoglobulin A a choroby ledvin. Vnitř Lék 2006; 52: 256-262.

22. Novak J, Moldoveanu Z, Renfrow MB et al. IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells. Contrib Nephrol 2007; 157: 134-138.

23. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, control trial. J Am Soc Nephrol 2004; 15: 157-163.

24. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863.

25. Rasche FM, Keller F, von Muller L et al. Sequential immunosuppressive therapy in progressive IgA nephropathy. Contrib Nephrol 2007; 157: 109-113.

26. Rasche FM, Keller F, Lepper PM et al. High dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up. Clin Exp Immunol 2006; 146: 47-53.

27. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456.

28. Ruggenenti P, Perna A, Gherardi G et al. Chronic proteinuric nephropathies: outcomes and treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kid Dis 2000; 35: 1155-1165.

29. Samuels JA, Strippoli GF, Craig JC et al. Immunosuppressive treatments for immunoglobulin A nephropathy. A meta-analysis of randomized controlled trials. Nephrology (Carlton) 2004; 9: 177-185.

30. Stojiljkovic L, Behnia R. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. Curr Pharm Des 2007; 13: 1335-1345.

31. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transpl 2000; 15: 34-42.

32. Tomino Y, Sakai H. Special Study Group (IgA nephropathy) in Progressive Renal Disease: Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan. 2nd version. Clin Exp Nephrol 2003; 7: 93-97.

33. Tomino Y. Treatment for IgA nephropathy. Contrib Nephrol 2007; 157: 8-12.

34. Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol 2004; 24: 256-268.

35. Woo KT, Lau YK, Wong KS et al. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 2000; 58: 2485-2491.

36. Welch TR, Fryer C, Shely E et al. Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr 1992; 121: 474-477.

37. Xie Y, Nishi S, Ueno M et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003; 63: 1861-1867.

38. Yoshikawa N, Ito H, Sakai T et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 1999; 10: 101-109.